GSAC Stock Overview
GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GelStat Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0004 |
| 52 Week High | US$0.0009 |
| 52 Week Low | US$0.0001 |
| Beta | 1.97 |
| 11 Month Change | -11.11% |
| 3 Month Change | 0% |
| 1 Year Change | -42.86% |
| 33 Year Change | -96.67% |
| 5 Year Change | -76.12% |
| Change since IPO | -99.93% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| GSAC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.1% | -1.1% | 1.1% |
| 1Y | -42.9% | 17.7% | 22.5% |
Return vs Industry: GSAC underperformed the US Pharmaceuticals industry which returned 19.2% over the past year.
Return vs Market: GSAC underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| GSAC volatility | |
|---|---|
| GSAC Average Weekly Movement | 34.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GSAC's share price has been volatile over the past 3 months.
Volatility Over Time: GSAC's weekly volatility has decreased from 42% to 34% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2 | Javier Acosta | www.gelstat.com |
GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers.
GelStat Corp. Fundamentals Summary
| GSAC fundamental statistics | |
|---|---|
| Market cap | US$1.20m |
| Earnings (TTM) | -US$206.58k |
| Revenue (TTM) | US$149.53k |
8.0x
P/S Ratio-5.8x
P/E RatioIs GSAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSAC income statement (TTM) | |
|---|---|
| Revenue | US$149.53k |
| Cost of Revenue | US$18.95k |
| Gross Profit | US$130.58k |
| Other Expenses | US$337.16k |
| Earnings | -US$206.58k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.000069 |
| Gross Margin | 87.33% |
| Net Profit Margin | -138.15% |
| Debt/Equity Ratio | -75.0% |
How did GSAC perform over the long term?
See historical performance and comparison